Evidence map›Paper›PMID 29851133›Full record

ArticleBiopharmaceutics & drug disposition2018

CBR1 rs9024 genotype status impacts the bioactivation of loxoprofen in human liver.

Adolfo Quiñones-Lombraña, Nasi Li, Virginia Del Solar, G Ekin Atilla-Gokcumen, Javier G Blanco

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biopharmaceutics & drug disposition, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 53% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Adolfo Quiñones-LombrañaUniversity at Buffalo, The State University of New York (SUNY), Department of Pharmaceutical Sciences, Buffalo, New York, USA.
Nasi LiUniversity at Buffalo, The State University of New York (SUNY), Department of Chemistry, Buffalo, New York, USA.
Virginia Del SolarUniversity at Buffalo, The State University of New York (SUNY), Department of Chemistry, Buffalo, New York, USA.
G Ekin Atilla-GokcumenUniversity at Buffalo, The State University of New York (SUNY), Department of Chemistry, Buffalo, New York, USA.
Javier G BlancoUniversity at Buffalo, The State University of New York (SUNY), Department of Pharmaceutical Sciences, Buffalo, New York, USA.ORCID http://orcid.org/0000-0003-3887-0370
University at Buffalo, State University of New York · US

Funding

PHARMACOGENETICS OF HUMAN CARBONYL REDUCTASESR01GM073646 · NIGMS · STATE UNIVERSITY OF NEW YORK AT BUFFALO · PI BLANCO, JAVIER GUILLERMO · 2005 to 2019
$4.1M
NIGMS NIH HHS R01 GM073646
6 · The paper itself

Abstract

Loxoprofen is an anti-inflammatory drug that requires bioactivation into the trans-OH metabolite to exert pharmacological activity. Evidence suggests that carbonyl reductase 1 (CBR1) is important during the bioactivation of loxoprofen. This study examined the impact of the functional single nucleotide polymorphism CBR1 rs9024 on the bioactivation of loxoprofen in a collection of human liver samples. The synthesis ratios of trans-OH loxoprofen/cis-OH loxoprofen were 33% higher in liver cytosols from donors homozygous for the CBR1 rs9024 G allele in comparison with the ratios in samples from donors with heterozygous GA genotypes. Complementary studies examined the impact of CBR1 rs9024 on the bioactivation of loxoprofen in lymphoblastoid cell lines. CBR1 rs9024 genotype status impacts the synthesis of the bioactive trans-OH metabolite of loxoprofen in human liver.

Indexed as

GenotypePolymorphism, Single NucleotideAlcohol OxidoreductasesAnti-Inflammatory Agents, Non-SteroidalCell Line, TumorGene Expression Regulation, EnzymologicHumansLiverPhenylpropionatesRNA, MessengerAlcohol OxidoreductasesAnti-Inflammatory Agents, Non-SteroidalCBR1 protein, humanloxoprofenPhenylpropionatesRNA, MessengerCBR1CBR1 rs9024loxoprofen

Identifiers

PMID29851133
PMCPMC6078805
OpenAlexW2806397824

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.